Phar­ma man­u­fac­tur­ers in In­dia, US lat­est to re­ceive qual­i­ty con­trol hits from the FDA

Two drug man­u­fac­tur­ers on op­po­site sides of the globe are fac­ing the heat from the FDA over sev­er­al qual­i­ty con­trol is­sues.

In­dia-based man­u­fac­tur­er Sun Phar­ma was hit with a Form 483 fol­low­ing an FDA in­spec­tion of its Mo­hali fa­cil­i­ty from Aug. 3-12.

The FDA found fail­ures when re­view­ing un­ex­plained dis­crep­an­cies re­gard­ing whether a batch al­ready had been dis­trib­uted at the lo­ca­tion.

The in­ves­ti­ga­tion found that there were in­stances of back­dat­ing, but Sun’s re­port was not thor­ough enough for the FDA to eval­u­ate the full scope of the of­fense. Sun did not in­ter­view all qual­i­ty as­sur­ance re­view­ers, but it did con­firm back­dat­ing by em­ploy­ees who had de­nied the prac­tice ini­tial­ly. Sun al­so did not have a thor­ough re­view of oth­er work per­formed by the em­ploy­ees, ac­cord­ing to the FDA re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER